NASH, Metabolic Syndrome, and Diabetes: How Sugar and Fat Increase the Risk of Developing Advanced Liver Disease

Oral administration of kynurenic acid delays the onset of type 2 diabetes in Goto-Kakizaki rats

“…KYNA is considered as a neuroprotector because it prevents excitotoxicity in neurons by acting as an antagonist at excitatory glutamate receptors [ [14] , [15] , [16] , [17] ]. It also acts as an immunomodulator in various inflammatory diseases [ 18 , 19 ], and accumulating evidence suggest that KYNA may also play an important role in energy metabolism [ [20] , [21] , [22] , [23] , [24] , [25] , [26] , [27] ] This last assumption is supported by several convincing arguments. TKP enzymes are expressed in tissues relevant for energy homeostasis such as adipose, skeletal muscle, liver and endocrine pancreas, blood vessel and heart [ 28 ].…”